{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03623945",
            "orgStudyIdInfo": {
                "id": "SH ABCD"
            },
            "organization": {
                "fullName": "Sanford Health",
                "class": "OTHER"
            },
            "briefTitle": "Autoantibodies in Breast Cancer Detection",
            "officialTitle": "Autoantibodies in Breast Cancer Detection",
            "acronym": "ABCD",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "autoantibodies-in-breast-cancer-detection"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-10",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2018-07-24",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-11-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-11-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2018-07-26",
            "studyFirstSubmitQcDate": "2018-08-06",
            "studyFirstPostDateStruct": {
                "date": "2018-08-09",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-10-19",
            "lastUpdatePostDateStruct": {
                "date": "2023-10-23",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Sanford Health",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Inanovate",
                    "class": "UNKNOWN"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Prospective, single-center study in women who have recently had an abnormal mammogram followed by a breast biopsy or women who have recently had a normal screening mammogram. We are no longer enrolling women who had normal Screening mammograms."
        },
        "conditionsModule": {
            "conditions": [
                "Breast Cancer"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": true,
            "targetDuration": "5 Years",
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 1550,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort A",
                    "description": "Patients who have recently had an abnormal mammogram, followed by a breast biopsy and an initial diagnosis of Stage I, II, III or IV invasive breast cancer, will be invited to participate. Stage I, II and III participants will be further categorized into high-risk and low-risk. For the purposes of this study, participants with at least one of the following will be considered high-risk; any triple negative cancer, any grade III cancer, lymph node involvement, tumor greater than 2cm, or any patient receiving cytotoxic chemotherapy.",
                    "interventionNames": [
                        "Other: Collection of blood"
                    ]
                },
                {
                    "label": "Cohort B",
                    "description": "Patients who have recently had an abnormal mammogram, followed by a breast biopsy and diagnosed with a benign but high-risk pathology, will be invited to participate. This includes, but is not limited to, atypical ductal hyperplasia, atypical lobular hyperplasia, ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), flat epithelia atypia or phylloides.\n\nAccrual to Cohort B is complete.",
                    "interventionNames": [
                        "Other: Collection of blood"
                    ]
                },
                {
                    "label": "Cohort C",
                    "description": "Patients who have recently had an abnormal mammogram, followed by a breast biopsy and diagnosed with a benign tumor, will be invited to participate. This includes, but is not limited to, fibroadenoma, papilloma, fibrocystic changes and Pseudoangiomatous stromal hyperplasia (PASH). Accrual to Cohort C is complete",
                    "interventionNames": [
                        "Other: Collection of blood"
                    ]
                },
                {
                    "label": "Cohort D",
                    "description": "Patients who have had a normal screening mammogram within the last 6 months will be invited to participate. Accrual to Cohort D is complete.",
                    "interventionNames": [
                        "Other: Collection of blood"
                    ]
                },
                {
                    "label": "Cohort E",
                    "description": "Patients who have recently had an abnormal mammogram, followed by a breast biopsy and an initial diagnosis of Stage I, II, III invasive breast cancer.\n\nPatients who have recently had an abnormal mammogram, followed by a breast biopsy, and diagnosed with a benign but high-risk pathology.\n\nCohort E has 3 sub-groups. For the purposes of this study, participants with a breast cancer will be categorized as E1-malignant high risk, of E2-malignant low risk.\n\nPatients who have recently had an abnormal mammogram, followed by a breast biopsy, and diagnosed with a benign but high-risk pathology, will be invited to participate.\n\nThese patients will be considered E3-benign high-risk.",
                    "interventionNames": [
                        "Other: Collection of blood"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "Collection of blood",
                    "description": "Collection of blood only to look at circulating autoantibodies that recognize breast cancer proteins to potentially be used as a biosensor for identifying patients with increased risk of having breast cancer",
                    "armGroupLabels": [
                        "Cohort A",
                        "Cohort B",
                        "Cohort C",
                        "Cohort D",
                        "Cohort E"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Autoantibodies for breast cancer diagnosis",
                    "description": "The data from Phase I will be tested and validated with newly diagnosed BCa patient samples from Cohort A, and age-matched healthy controls taken from Cohort D, and a risk score will be developed based on a composite of autoantibodies for breast cancer diagnosis. A Cox Proportional Hazards (PH) Regression will be used to analyze a case-cohort study design to validate the risk score by identifying breast cancer cases from those cases in Cohorts B, C and D.",
                    "timeFrame": "5 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Inclusion Criteria:\n\nAll Cohorts:\n\n* Women age 18 and older\n* Understand and provide informed consent and HIPAA Authorization prior to initiation of any study-specific procedures\n\nCohort A:\n\n* Recent abnormal mammogram followed by a breast biopsy\n* Initial diagnosis of Stage I, II, III or IV invasive breast cancer\n\nCohort B:\n\n* Recent abnormal mammogram followed by a breast biopsy\n* Diagnosed benign breast tumor with high-risk pathology. This would include, but is not limited to, atypical ductal hyperplasia, atypical lobular hyperplasia, lobular carcinoma in situ (LCIS), ductal carcinoma in situ (DCIS), flat epithelia atypia and phylloides\n\nCohort C:\n\n* Recent abnormal mammogram followed by a breast biopsy\n* Diagnosed benign breast tumor. This would include, but is not limited to, fibroadenoma, papilloma, fibrocystic changes, and Pseudoangiomatous stromal hyperplasia (PASH)\n\nCohort D:\n\n\u2022 Normal screening mammogram within the last 6 months\n\nExclusion Criteria:\n\n* All Cohorts:\n\n  * Men.\n  * Unable or unwilling to give written informed consent\n\nCohort A:\n\n\u2022 History of cancer other than non-melanoma basal or squamous cell skin carcinoma, ductal carcinoma in situ (DCIS) and cervical carcinoma in situ.\n\nCohort B:\n\n\u2022 History of cancer other than non-melanoma basal or squamous cell skin carcinoma and cervical carcinoma in situ.\n\nCohort C:\n\n\u2022 History of cancer other than non-melanoma basal or squamous cell skin carcinoma and cervical carcinoma in situ.\n\nCohort D:\n\n* History of cancer other than non-melanoma basal or squamous cell skin carcinoma and cervical carcinoma in situ.\n* History of or current autoimmune disease including but not limited to Sjogrens Syndrome, Systemic Sclerosis (SSc), Scleroderma (Scl) and Dermatomyositis, Systemic Lupus Erythematosus, Multiple Sclerosis, Type I Diabetes, Rheumatoid Arthritis\n* History of abnormal mammogram",
            "healthyVolunteers": false,
            "sex": "FEMALE",
            "genderBased": true,
            "genderDescription": "Female patients only",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Women who have recently had an abnormal mammogram followed by a breast biopsy or women who have recently had a normal screening mammogram.\n\nThe study team will enroll approximately 1,550 participants at Sanford Health in Sioux Falls, SD and Fargo, ND. Cohort A= 300 participants, Cohort B= 250 participants, Cohort C= 500 participants and Cohort D= 500 participants.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Jenna Hove, RN BSN",
                    "role": "CONTACT",
                    "phone": "605-312-3337",
                    "email": "jenna.hove@sanfordhealth.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Kristi Egland, PhD",
                    "affiliation": "Sanford Health",
                    "role": "STUDY_CHAIR"
                }
            ],
            "locations": [
                {
                    "facility": "Sanford Health",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Fargo",
                    "state": "North Dakota",
                    "zip": "58104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jennifer Rasmussen, RN",
                            "role": "CONTACT",
                            "phone": "701-234-7258",
                            "email": "jennifer.f.rasmussen@sanfordhealth.org"
                        },
                        {
                            "name": "Kristi Egland, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 46.87719,
                        "lon": -96.7898
                    }
                },
                {
                    "facility": "Sanford Health",
                    "status": "RECRUITING",
                    "city": "Sioux Falls",
                    "state": "South Dakota",
                    "zip": "57104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Laurie Auch",
                            "role": "CONTACT",
                            "phone": "605-312-3325",
                            "email": "laurie.auch@sanfordhealth.org"
                        },
                        {
                            "name": "Kristi Egland, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.54997,
                        "lon": -96.70033
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "No plan to share individual participant data"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "asFound": "Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4625",
                    "name": "Autoantibodies",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}